Topical Skin Infection Treatment Drug Pipeline Analysis Report 2024

Skin and soft tissue infections have an incidence of 24.8 cases per 1,000 people. Research reveals that children under the age of 5 and adults over 65 years are more prone to developing a skin infection. As a result, leading pharmaceutical companies are involved in designing a diverse range of drugs that cater to a wide spectrum of affected individuals.

Key Takeaway

• Major companies involved in the topical skin infection treatment pipeline drugs market include GlaxoSmithKline, Pfizer, and Hoth Therapeutics Inc. among others.

• Leading drugs currently under pipeline include Topical SB-275833 Ointment, 1%, Retapamulin, AN2690 Topical Solution, and Topical HT-001, among others.

• Regulatory authorities such as the United States FDA and EMA play an essential role in the drug pipeline for topical skin infection treatment as they are offering breakthrough designations to manage the condition.

Report Coverage

The Topical Skin Infection TreatmentDrug Pipeline Insight Report by Expert Market Research gives comprehensive insights into topical skin infection treatmentdrugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Topical skin infection treatment. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The topical skin infection treatment pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from topical skin infection treatment.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to topical skin infection treatment.

Topical Skin Infection Treatment Drug Pipeline Outlook

Skin infection can be caused by various types of germs such as bacteria, viruses, fungi and parasites. Common bacterial skin infections include cellulitis, impetigo, and staphylococcal (staph) infections. Shingles, warts and herpes are examples of viral skin infections while yeast infections and athlete's foot are fungal infections. Individuals having poor circulation, diabetes, immune system diseases or obesity are at a higher risk of developing skin infections. Symptoms can include rashes, swelling, redness, pain, pus, and itching.

The treatment for skin infections varies on the type of infection and seriousness. Topical solutions such as creams or lotions are commonly advised by healthcare professionals. In January 2024, the United States FDA approved berdazimer gel 10.3% for the treatment of molluscum contagiosum (MC) in adults. Several drugs are under evaluation to treat and manage various skin infections effectively.

Topical Skin Infection Treatment – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of Topical skin infection treatmentdrugs based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)

• Mid-Stage Products (Phase 2)

• Early-Stage Products (Phase I)

• Preclinical and Discovery Stage Products

By Drug Class

EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:

• Antibiotics

• Antifungals

• Antivirals

• Corticosteroids

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Topical

Topical Skin Infection Treatment – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for topical skin infection treatment. There are around 67 drugs in phase II of topical skin infection treatment drugs.

Topical Skin Infection Treatment – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under topical skin infection treatmentpipeline analysis include antibiotics, antifungals, antivirals, and corticosteroids, among others. The medication depends on the type of infection and its severity. For instance, antibiotics are used to treat bacterial infections while corticosteroids are often used in combination with antimicrobial agents to reduce inflammation.

Topical Skin Infection TreatmentClinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the topical skin infection treatmentdrug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in topical skin infection treatment clinical trials:

• GlaxoSmithKline

• Fraser Health

• Pfizer

• Taro Pharmaceuticals USA

• Medical Life Care Planners, LLC

• Hoth Therapeutics, Inc.

Topical Skin Infection Treatment– Emerging Drugs Profile

Topical SB-275833 Ointment, 1%

This topical is under investigation to treat impetigo in adults and children. Sponsored by GlaxoSmithKline, the ointment is in a randomised, observer-blind, multicentre, non-inferiority, comparative, Phase III study and is being evaluated for its safety and efficacy.

Retapamulin

Currently, in Phase III of an interventional study, Retapamulin is under evaluation to treat patients with SITL or impetigo due to MRSA (Methicillin-Resistant Staphylococcus Aureus).

AN2690 Topical Solution

Pfizer’s AN2690 Topical Solution is being evaluated to treat onychomycosis of the toenail. The medication is in Phase 3 of a randomized, multi-center study that has around 600 patients.

Topical HT-00

This topical gel, developed by Hoth Therapeutics Inc., is under investigation for the treatment of EGFR inhibitor-induced skin toxicities. As a part of the study, the participants will apply the gel once a day for 6 weeks and will be assessed for its safety and efficacy.

Reasons To Buy This Report

The Topical Skin Infection Treatment Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for topical skin infection treatment. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within topical skin infection treatment pipeline insights.

Key Questions Answered in the Topical Skin Infection Treatment– Pipeline Insight Report

• What is the current landscape of topical skin infection treatment pipeline drugs? 
• How many companies are developing topical skin infection treatment drugs? 
• How many phase III and phase IV drugs are currently present in topical skin infection treatment pipeline drugs? 
• Which companies/institutions are leading the topical skin infection treatment drug development? 
• What is the efficacy and safety profile of topical skin infection treatment pipeline drugs? 
• What are the opportunities and challenges present in the topical skin infection treatment drug pipeline landscape? 
• Which company is conducting major trials for topical skin infection treatment drugs? 
• What geographies are covered in topical skin infection treatment? 
• What are emerging trends in topical skin infection treatment clinical trials?

Related Reports

 Acute Bacterial Skin and Skin Structure Infections Treatment Market

Clinical Trials Market